DYN as reported
- Net Income
- −$519M
Net Income · +26% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$480M
Free Cash Flow · +33% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.30
EPS · −15% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$519M | +26% | Q2 2026 |
| EPS | −$3.30 | −15% | Q2 2026 |
| ROE | −58% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
| ROIC | 4638% | n/a | Q2 2026 |
| Free Cash Flow | −$480M | +33% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Dyne Therapeutics, Inc. (DYN) - Net IncomeNet IncomeDyne Therapeutics, Inc. (DYN)